AU741199B2 - Modulators of beta-amyloid peptide aggregation comprising D-amino acids - Google Patents

Modulators of beta-amyloid peptide aggregation comprising D-amino acids Download PDF

Info

Publication number: AU741199B2
Authority: AU; Australia
Prior art keywords: phe; phenylalanine; leu; val; compound
Prior art date: 1996-08-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU42387/97A

Other languages

English (en)

Other versions

AU4238797A (en

Inventor

Christopher C. Arico-Muendel

Joseph Chin

Mark A Findeis

Malcolm L. Gefter

Neil J. Hayward

Michael Kelley

Sonja Komar-Panicucci

Jung-Ja Lee

Susan Molineaux

Gary Musso

Kathryn Phillips

Ethan R Signer

James Wakefield

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Praecis Pharmaceuticals Inc

Original Assignee

Praecis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1997-08-27

Publication date

2001-11-22

1996-08-27 Priority claimed from US08/703,675 external-priority patent/US6303567B1/en

1997-08-27 Application filed by Praecis Pharmaceuticals Inc filed Critical Praecis Pharmaceuticals Inc

1998-03-19 Publication of AU4238797A publication Critical patent/AU4238797A/en

2001-11-22 Application granted granted Critical

2001-11-22 Publication of AU741199B2 publication Critical patent/AU741199B2/en

2002-02-11 Priority to AU15539/02A priority Critical patent/AU769915B2/en

2004-05-12 Priority to AU2004202014A priority patent/AU2004202014B2/en

2017-08-27 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

150000008574 D-amino acids Chemical class 0.000 title abstract description 81
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract description 19
230000006919 peptide aggregation Effects 0.000 title abstract description 4
150000001875 compounds Chemical class 0.000 claims abstract description 307
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 222
238000000034 method Methods 0.000 claims abstract description 53
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
125000003368 amide group Chemical group 0.000 claims abstract description 23
238000011282 treatment Methods 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
125000003118 aryl group Chemical group 0.000 claims abstract description 17
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 16
201000010099 disease Diseases 0.000 claims abstract description 12
230000002776 aggregation Effects 0.000 claims description 143
238000004220 aggregation Methods 0.000 claims description 143
-1 phenylacetyl Chemical group 0.000 claims description 119
102000004196 processed proteins & peptides Human genes 0.000 claims description 80
239000000126 substance Substances 0.000 claims description 20
230000002401 inhibitory effect Effects 0.000 claims description 19
239000012472 biological sample Substances 0.000 claims description 16
230000002285 radioactive effect Effects 0.000 claims description 15
206010002022 amyloidosis Diseases 0.000 claims description 14
238000000338 in vitro Methods 0.000 claims description 14
125000002160 cholyl group Chemical group [H]C([H])([C@]1(C([C@@]2([H])O[H])([H])[H])[H])[C@@](O[H])([H])C([H])([H])C([H])([H])[C@]1(C([H])([H])[H])[C@]1([H])[C@]2([H])[C@]2([H])C([H])([H])C([H])([H])[C@@]([C@](C([H])([H])[H])(C(C(C(=O)[*])([H])[H])([H])[H])[H])([H])[C@@]2(C([H])([H])[H])[C@](O[H])([H])C1([H])[H] 0.000 claims description 11
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
229910052740 iodine Inorganic materials 0.000 claims description 9
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
239000011630 iodine Substances 0.000 claims description 7
229910052713 technetium Inorganic materials 0.000 claims description 6
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 6
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
KUNFMZSTKSLIEY-NWKMIUOTSA-N (2r)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-NWKMIUOTSA-N 0.000 claims 1
210000004899 c-terminal region Anatomy 0.000 abstract description 27
125000000217 alkyl group Chemical group 0.000 abstract description 19
125000004122 cyclic group Chemical group 0.000 abstract description 16
125000000623 heterocyclic group Chemical group 0.000 abstract description 13
125000003367 polycyclic group Chemical group 0.000 abstract description 11
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract description 3
229930182819 D-leucine Natural products 0.000 abstract description 3
229930182832 D-phenylalanine Natural products 0.000 abstract description 2
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 description 132
150000001413 amino acids Chemical class 0.000 description 128
229940024606 amino acid Drugs 0.000 description 123
238000003556 assay Methods 0.000 description 55
206010029350 Neurotoxicity Diseases 0.000 description 41
206010044221 Toxic encephalopathy Diseases 0.000 description 41
230000007135 neurotoxicity Effects 0.000 description 41
231100000228 neurotoxicity Toxicity 0.000 description 41
239000000243 solution Substances 0.000 description 37
238000012360 testing method Methods 0.000 description 36
210000004556 brain Anatomy 0.000 description 30
239000000203 mixture Substances 0.000 description 29
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 26
125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 25
125000003275 alpha amino acid group Chemical group 0.000 description 25
150000001408 amides Chemical class 0.000 description 23
238000006467 substitution reaction Methods 0.000 description 22
239000002253 acid Substances 0.000 description 21
210000004027 cell Anatomy 0.000 description 21
238000001727 in vivo Methods 0.000 description 21
230000008499 blood brain barrier function Effects 0.000 description 20
150000008575 L-amino acids Chemical group 0.000 description 19
230000015572 biosynthetic process Effects 0.000 description 19
210000001175 cerebrospinal fluid Anatomy 0.000 description 19
125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 18
230000008878 coupling Effects 0.000 description 17
238000010168 coupling process Methods 0.000 description 17
238000005859 coupling reaction Methods 0.000 description 17
239000000178 monomer Substances 0.000 description 17
239000000523 sample Substances 0.000 description 17
125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 description 16
125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 description 16
125000000539 amino acid group Chemical group 0.000 description 16
230000006911 nucleation Effects 0.000 description 16
238000010899 nucleation Methods 0.000 description 16
238000006116 polymerization reaction Methods 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
230000004048 modification Effects 0.000 description 14
238000012986 modification Methods 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 13
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 13
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 13
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 13
235000018102 proteins Nutrition 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
239000011347 resin Substances 0.000 description 13
229920005989 resin Polymers 0.000 description 13
230000032258 transport Effects 0.000 description 13
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
230000008021 deposition Effects 0.000 description 11
238000009472 formulation Methods 0.000 description 11
JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
208000037259 Amyloid Plaque Diseases 0.000 description 10
XOEDPXDZJHBQIX-ULQDDVLXSA-N Leu-Val-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOEDPXDZJHBQIX-ULQDDVLXSA-N 0.000 description 10
NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical group C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
108010073025 phenylalanylphenylalanine Proteins 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
125000003277 amino group Chemical group 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
230000004060 metabolic process Effects 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 7
230000003941 amyloidogenesis Effects 0.000 description 7
238000013459 approach Methods 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 7
230000008569 process Effects 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
239000000651 prodrug Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
238000007385 chemical modification Methods 0.000 description 6
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
239000000835 fiber Substances 0.000 description 6
238000003384 imaging method Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
239000000816 peptidomimetic Substances 0.000 description 6
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 6
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000010254 subcutaneous injection Methods 0.000 description 6
239000007929 subcutaneous injection Substances 0.000 description 6
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 5
239000004380 Cholic acid Substances 0.000 description 5
229920000858 Cyclodextrin Polymers 0.000 description 5
229930182831 D-valine Natural products 0.000 description 5
241000700159 Rattus Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
239000003613 bile acid Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
235000019416 cholic acid Nutrition 0.000 description 5
229960002471 cholic acid Drugs 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 4
FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 description 4
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
JAQNUEWEJWBVAY-WBAXXEDZSA-N Ala-Phe-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 JAQNUEWEJWBVAY-WBAXXEDZSA-N 0.000 description 4
MSFITIBEMPWCBD-ULQDDVLXSA-N Leu-Val-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MSFITIBEMPWCBD-ULQDDVLXSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
238000007792 addition Methods 0.000 description 4
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
239000011616 biotin Substances 0.000 description 4
210000004781 brain capillary Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000009510 drug design Methods 0.000 description 4
238000001493 electron microscopy Methods 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
201000008319 inclusion body myositis Diseases 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
108010065135 phenylalanyl-phenylalanyl-phenylalanine Proteins 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000013222 sprague-dawley male rat Methods 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical group CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000002068 Glycopeptides Human genes 0.000 description 3
108010015899 Glycopeptides Proteins 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108010066788 PPI 368 Proteins 0.000 description 3
CBENHWCORLVGEQ-HJOGWXRNSA-N Phe-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CBENHWCORLVGEQ-HJOGWXRNSA-N 0.000 description 3
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
108010045517 Serum Amyloid P-Component Proteins 0.000 description 3
102100036202 Serum amyloid P-component Human genes 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
125000000304 alkynyl group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
239000013068 control sample Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
229940039227 diagnostic agent Drugs 0.000 description 3
239000000032 diagnostic agent Substances 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
108010028295 histidylhistidine Proteins 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
150000002466 imines Chemical class 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
239000002502 liposome Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
239000003607 modifier Substances 0.000 description 3
231100000189 neurotoxic Toxicity 0.000 description 3
230000002887 neurotoxic effect Effects 0.000 description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
150000003003 phosphines Chemical class 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
238000002600 positron emission tomography Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
235000019260 propionic acid Nutrition 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
150000003346 selenoethers Chemical class 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
238000011191 terminal modification Methods 0.000 description 3
150000003568 thioethers Chemical class 0.000 description 3
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 2
208000018282 ACys amyloidosis Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 2
XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101800004538 Bradykinin Proteins 0.000 description 2
102400000967 Bradykinin Human genes 0.000 description 2
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 description 2
201000010374 Down Syndrome Diseases 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
102000058063 Glucose Transporter Type 1 Human genes 0.000 description 2
YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 2
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
108010065395 Neuropep-1 Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
108091006296 SLC2A1 Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
108010033576 Transferrin Receptors Proteins 0.000 description 2
102000007238 Transferrin Receptors Human genes 0.000 description 2
206010044688 Trisomy 21 Diseases 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
BCBFMJYTNKDALA-UFYCRDLUSA-N Val-Phe-Phe Chemical compound N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O BCBFMJYTNKDALA-UFYCRDLUSA-N 0.000 description 2
239000003875 Wang resin Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
108010005233 alanylglutamic acid Proteins 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
230000009920 chelation Effects 0.000 description 2
238000010382 chemical cross-linking Methods 0.000 description 2
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
229960001091 chenodeoxycholic acid Drugs 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
108010087823 glycyltyrosine Proteins 0.000 description 2
108010037850 glycylvaline Proteins 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
210000001087 myotubule Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
108010084572 phenylalanyl-valine Proteins 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
239000012857 radioactive material Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
230000003068 static effect Effects 0.000 description 2
150000003431 steroids Chemical group 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
229960001685 tacrine Drugs 0.000 description 2
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000007306 turnover Effects 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 2
229960001661 ursodiol Drugs 0.000 description 2
239000004474 valine Substances 0.000 description 2
JTTHKOPSMAVJFE-SECBINFHSA-N (2r)-2-azaniumyl-4-phenylbutanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC1=CC=CC=C1 JTTHKOPSMAVJFE-SECBINFHSA-N 0.000 description 1
HUOYGRNYKOUAFE-QMMMGPOBSA-N (2s)-2-(iodoamino)-3-phenylpropanoic acid Chemical class OC(=O)[C@@H](NI)CC1=CC=CC=C1 HUOYGRNYKOUAFE-QMMMGPOBSA-N 0.000 description 1
SICITCLFXRGKJW-IIZANFQQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 SICITCLFXRGKJW-IIZANFQQSA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
QYIXCDOBOSTCEI-DSHIFKSRSA-N (3r,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QYIXCDOBOSTCEI-DSHIFKSRSA-N 0.000 description 1
QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
VOXXWSYKYCBWHO-MRVPVSSYSA-N (R)-3-phenyllactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-MRVPVSSYSA-N 0.000 description 1
VOXXWSYKYCBWHO-QMMMGPOBSA-N (S)-3-phenyllactic acid Chemical compound OC(=O)[C@@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-QMMMGPOBSA-N 0.000 description 1
UFIVEPVSAGBUSI-REOHCLBHSA-N (S)-dihydroorotic acid Chemical compound OC(=O)[C@@H]1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-REOHCLBHSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 1
125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
102100033639 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
DHONNEYAZPNGSG-UBHSHLNASA-N Ala-Val-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DHONNEYAZPNGSG-UBHSHLNASA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 1
KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 1
TVVYVAUGRHNTGT-UGYAYLCHSA-N Asp-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O TVVYVAUGRHNTGT-UGYAYLCHSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
OOZRTYUMPAKJOO-UHFFFAOYSA-N C(CC)(=O)OC(CC)=O.C(CCCCC)(=O)OC(CCCCC)=O.C(C(C)C)(=O)OC(C(C)C)=O.C(CCC)(=O)OC(CCC)=O Chemical compound C(CC)(=O)OC(CC)=O.C(CCCCC)(=O)OC(CCCCC)=O.C(C(C)C)(=O)OC(C(C)C)=O.C(CCC)(=O)OC(CCC)=O OOZRTYUMPAKJOO-UHFFFAOYSA-N 0.000 description 1
HFCLMQYGEYMSRZ-PBMMXLDCSA-N CC(C)[C@@H](N)C(O)=O.CC(C)C[C@@H](N)C(O)=O.OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](C)NC(=O)CC1=CC=CN=C1 Chemical compound CC(C)[C@@H](N)C(O)=O.CC(C)C[C@@H](N)C(O)=O.OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](C)NC(=O)CC1=CC=CN=C1 HFCLMQYGEYMSRZ-PBMMXLDCSA-N 0.000 description 1
NIMOQCLHSDFOBY-OINAORLWSA-N CC(C)[C@@H](N)C(O)=O.CC(C)C[C@@H](N)C(O)=O.OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@H](N)CC1=CC=CC=C1.OCC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 Chemical compound CC(C)[C@@H](N)C(O)=O.CC(C)C[C@@H](N)C(O)=O.OC(=O)[C@H](N)CC1=CC=CC=C1.OC(=O)[C@H](N)CC1=CC=CC=C1.OCC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 NIMOQCLHSDFOBY-OINAORLWSA-N 0.000 description 1
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
206010051290 Central nervous system lesion Diseases 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
150000008563 D-leucines Chemical class 0.000 description 1
LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 description 1
150000008566 D-phenylalanines Chemical class 0.000 description 1
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
229930195709 D-tyrosine Natural products 0.000 description 1
150000008573 D-valines Chemical class 0.000 description 1
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
LXAUHIRMWXQRKI-XHNCKOQMSA-N Glu-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O LXAUHIRMWXQRKI-XHNCKOQMSA-N 0.000 description 1
KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
YSDLIYZLOTZZNP-UWVGGRQHSA-N Gly-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN YSDLIYZLOTZZNP-UWVGGRQHSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
VOXXWSYKYCBWHO-UHFFFAOYSA-N HO-Phe-OH Natural products OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 description 1
NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
QZZIBQZLWBOOJH-PEDHHIEDSA-N Ile-Ile-Val Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)O QZZIBQZLWBOOJH-PEDHHIEDSA-N 0.000 description 1
GMUYXHHJAGQHGB-TUBUOCAGSA-N Ile-Thr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GMUYXHHJAGQHGB-TUBUOCAGSA-N 0.000 description 1
241000102542 Kara Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
UZVWDRPUTHXQAM-FXQIFTODSA-N Met-Asp-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O UZVWDRPUTHXQAM-FXQIFTODSA-N 0.000 description 1
CQRGINSEMFBACV-WPRPVWTQSA-N Met-Val-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O CQRGINSEMFBACV-WPRPVWTQSA-N 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
WNYLGANFQGWSNO-UHFFFAOYSA-N N1=CC=C(C2=CC=CC=C12)C(=O)O.N1=CC=C(C=C1)CC(=O)O.N1=CC(=CC=C1)CC(=O)O.CC(CCC(=O)O)C Chemical compound N1=CC=C(C2=CC=CC=C12)C(=O)O.N1=CC=C(C=C1)CC(=O)O.N1=CC(=CC=C1)CC(=O)O.CC(CCC(=O)O)C WNYLGANFQGWSNO-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
BNTPLKHBAXVBJG-UHFFFAOYSA-N OC1=C(C=CC(=O)O)C=CC=C1.OC1=CC=C(C=CC(=O)O)C=C1.OC=1C=C(C=CC(=O)O)C=CC1 Chemical compound OC1=C(C=CC(=O)O)C=CC=C1.OC1=CC=C(C=CC(=O)O)C=C1.OC=1C=C(C=CC(=O)O)C=CC1 BNTPLKHBAXVBJG-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 1
MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 description 1
RYQWALWYQWBUKN-FHWLQOOXSA-N Phe-Phe-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RYQWALWYQWBUKN-FHWLQOOXSA-N 0.000 description 1
GRVMHFCZUIYNKQ-UFYCRDLUSA-N Phe-Phe-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GRVMHFCZUIYNKQ-UFYCRDLUSA-N 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102400000267 Rhomboid-related protein 2, N-terminal fragment Human genes 0.000 description 1
101800000645 Rhomboid-related protein 2, N-terminal fragment Proteins 0.000 description 1
VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
CJEHCEOXPLASCK-MEYUZBJRSA-N Thr-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=C(O)C=C1 CJEHCEOXPLASCK-MEYUZBJRSA-N 0.000 description 1
208000037280 Trisomy Diseases 0.000 description 1
101800000716 Tumor necrosis factor, membrane form Proteins 0.000 description 1
SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
SDUBQHUJJWQTEU-XUXIUFHCSA-N Val-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C(C)C)N SDUBQHUJJWQTEU-XUXIUFHCSA-N 0.000 description 1
DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 1
OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
WBPFYNYTYASCQP-CYDGBPFRSA-N Val-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N WBPFYNYTYASCQP-CYDGBPFRSA-N 0.000 description 1
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000006933 amyloid-beta aggregation Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001896 anti-amyloidogenic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
101150031224 app gene Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 description 1
229950006858 bufogenin Drugs 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
210000000269 carotid artery external Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000005284 excitation Effects 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229940014144 folate Drugs 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
KVMMIDQDXZOPAB-UHFFFAOYSA-N isoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C=NC(C(=O)O)=CC2=C1 KVMMIDQDXZOPAB-UHFFFAOYSA-N 0.000 description 1
150000003951 lactams Chemical group 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
108010064235 lysylglycine Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
210000002682 neurofibrillary tangle Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000501 nonneurotoxic Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940115458 pantolactone Drugs 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
108010073101 phenylalanylleucine Proteins 0.000 description 1
PETXWIMJICIQTQ-UHFFFAOYSA-N phenylmethoxymethanol Chemical group OCOCC1=CC=CC=C1 PETXWIMJICIQTQ-UHFFFAOYSA-N 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
231100000316 potential neurotoxicity Toxicity 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000022256 primary systemic amyloidosis Diseases 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108010070643 prolylglutamic acid Proteins 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
ATLJNLYIJOCWJE-UHFFFAOYSA-N resibufogenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C=1C=CC(=O)OC=1 ATLJNLYIJOCWJE-UHFFFAOYSA-N 0.000 description 1
230000004044 response Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000012085 test solution Substances 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000031998 transcytosis Effects 0.000 description 1
230000032895 transmembrane transport Effects 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
239000002691 unilamellar liposome Substances 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
231100000747 viability assay Toxicity 0.000 description 1
238000003026 viability measurement method Methods 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU42387/97A 1996-08-27 1997-08-27 Modulators of beta-amyloid peptide aggregation comprising D-amino acids Ceased AU741199B2 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
AU15539/02A AU769915B2 (en)	1996-08-27	2002-02-11	Modulators of beta-amyloid peptide aggregation comprising D-amino acids
AU2004202014A AU2004202014B2 (en)	1996-08-27	2004-05-12	Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US08/703675		1996-08-27
US08/703,675 US6303567B1 (en)	1995-03-14	1996-08-27	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US89734297A	1997-07-21	1997-07-21
US08/897342		1997-07-21
PCT/US1997/015166 WO1998008868A1 (en)	1996-08-27	1997-08-27	MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU15539/02A Division AU769915B2 (en)	1996-08-27	2002-02-11	Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Publications (2)

Publication Number	Publication Date
AU4238797A AU4238797A (en)	1998-03-19
AU741199B2 true AU741199B2 (en)	2001-11-22

Family

ID=27107183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU42387/97A Ceased AU741199B2 (en)	1996-08-27	1997-08-27	Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Country Status (10)

Country	Link
EP (2)	EP0929574B1 (de)
JP (1)	JP2001500852A (de)
AT (1)	ATE298765T1 (de)
AU (1)	AU741199B2 (de)
CA (1)	CA2262453A1 (de)
DE (1)	DE69733655T2 (de)
DK (1)	DK0929574T3 (de)
ES (1)	ES2245003T3 (de)
PT (1)	PT929574E (de)
WO (1)	WO1998008868A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277826B1 (en)	1996-08-27	2001-08-21	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) *	1995-10-27	1999-11-16	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1997021728A1 (en)	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
EP1015013A4 (de) *	1997-01-10	2002-07-24	Massachusetts Inst Technology	Behandlung von neurotoxizität in alzheimer'schen krankheit durch beta-amyloid peptiden
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
EP1161449B1 (de)	1999-03-04	2007-07-04	Praecis Pharmaceuticals Incorporated	Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
EP1870419A3 (de) *	1999-03-04	2008-01-02	Praecis Pharmaceuticals Incorporated	Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren
WO2000068263A2 (en) *	1999-05-05	2000-11-16	Neurochem, Inc.	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2001034631A2 (en) *	1999-11-05	2001-05-17	Axonyx, Inc.	PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
NZ540564A (en) *	1999-11-29	2007-04-27	Neurochem Int Ltd	Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
CA2398567A1 (en) *	2000-02-11	2001-08-16	Praecis Pharmaceuticals Incorporated	Methods for enhancing the bioavailability of a drug
GB2363984A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en)	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 7-hydroxyepiandrosterone
US7067550B2 (en)	2000-11-03	2006-06-27	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's Disease
EP1341548A4 (de)	2000-11-03	2006-06-14	Massachusetts Inst Technology	VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
CA2434831C (en) *	2001-01-17	2012-03-06	Robert H. Zimmer	Polypeptide drug substances
JP4354180B2 (ja) *	2001-12-26	2009-10-28	武田薬品工業株式会社	軽度認知障害治療剤
US20040052928A1 (en)	2002-09-06	2004-03-18	Ehud Gazit	Peptides and methods using same for diagnosing and treating amyloid-associated diseases
KR101011657B1 (ko)	2002-03-01	2011-01-28	다케다 야쿠힌 고교 가부시키가이샤	항우울제
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US6846640B2 (en)	2002-04-30	2005-01-25	Pharmacia & Upjohn Company	Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP5137400B2 (ja) *	2003-06-30	2013-02-06	テルアヴィヴユニヴァーシティフューチャーテクノロジーディヴェロップメントエル．ピー．	アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
WO2006066089A1 (en)	2004-12-15	2006-06-22	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized antibodies that recognize beta amyloid peptide
WO2007020888A1 (ja)	2005-08-12	2007-02-22	Takeda Pharmaceutical Company Limited	脳・神経細胞保護剤および睡眠障害治療薬
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
EP2089419A2 (de) *	2006-10-27	2009-08-19	Zapaloid Limited	Inhibierung der beta-amyloid-aggregation
US8236766B2 (en)	2006-11-10	2012-08-07	Cara Therapeutics, Inc.	Uses of synthetic peptide amides
US8906859B2 (en)	2006-11-10	2014-12-09	Cera Therapeutics, Inc.	Uses of kappa opioid synthetic peptide amides
MX2009005000A (es)	2006-11-10	2009-10-12	Cara Therapeutics Inc	Amidas de peptidos sinteticos.
US7842662B2 (en)	2006-11-10	2010-11-30	Cara Therapeutics, Inc.	Synthetic peptide amide dimers
US7713937B2 (en)	2006-11-10	2010-05-11	Cara Therapeutics, Inc.	Synthetic peptide amides and dimeric forms thereof
CA2676715A1 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
RS53416B (sr)	2009-03-10	2014-12-31	Takeda Pharmaceutical Company Limited	Derivati benzofurana
EP2625170A1 (de)	2010-10-07	2013-08-14	Takeda Pharmaceutical Company Limited	1,4-oxazepanderivate
CN103298826A (zh)	2010-11-15	2013-09-11	特拉维夫大学拉莫特有限公司	用于治疗淀粉样纤维形成相关疾病的二肽类似物
PL2763979T3 (pl)	2011-10-07	2019-06-28	Takeda Pharmaceutical Company Limited	Związki 1-arylokarbonyl-4-oksy-piperydynowe użyteczne do leczenia chorób neurodegeneracyjnych
US9296746B2 (en)	2012-10-16	2016-03-29	Takeda Pharmaceutical Company Limited	Heterocyclic compound
PE20151162A1 (es)	2012-12-11	2015-08-28	Takeda Pharmaceutical	Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h)
JP6272832B2 (ja)	2013-04-04	2018-01-31	武田薬品工業株式会社	複素環化合物
EP2982670B1 (de)	2013-04-04	2018-11-07	Takeda Pharmaceutical Company Limited	Heterocyclische verbindung
EP3152198B1 (de)	2014-06-09	2019-02-27	Takeda Pharmaceutical Company Limited	Radioaktiv markierte verbindungen
LT3984994T (lt)	2016-02-04	2024-10-10	Takeda Pharmaceutical Company Limited	Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti
US11059780B2 (en)	2017-03-08	2021-07-13	Takeda Pharmaceutical Company Limited	Substituted pyrrolidine compound and use thereof
EP3660003B1 (de)	2017-07-28	2024-01-24	Takeda Pharmaceutical Company Limited	Heterocyclische verbindung
US10428023B2 (en)	2017-08-03	2019-10-01	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
US10807987B2 (en)	2018-03-28	2020-10-20	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
JP7339250B2 (ja)	2018-06-29	2023-09-05	武田薬品工業株式会社	複素環化合物およびその用途
WO2020153414A1 (ja)	2019-01-24	2020-07-30	武田薬品工業株式会社	複素環化合物及びその用途
TW202523658A (zh)	2019-05-24	2025-06-16	美商賽吉醫療公司	化合物、組合物及使用方法
AU2020346456A1 (en)	2019-09-13	2022-04-14	Takeda Pharmaceutical Company Limited	TAK-925 for use in treating narcolepsy
KR20220062361A (ko)	2019-09-13	2022-05-16	다케다 야쿠힌 고교 가부시키가이샤	과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
JP2021050161A (ja)	2019-09-25	2021-04-01	武田薬品工業株式会社	複素環化合物及びその用途
JP2021080177A (ja)	2019-11-14	2021-05-27	武田薬品工業株式会社	複素環化合物及びその用途
US12448377B2 (en)	2019-11-27	2025-10-21	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JP2021183587A (ja)	2020-05-22	2021-12-02	武田薬品工業株式会社	複素環化合物
JP2023550654A (ja)	2020-11-25	2023-12-04	セージセラピューティクス，インコーポレイテッド	神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物
TW202302100A (zh)	2021-03-12	2023-01-16	日商武田藥品工業股份有限公司	食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
US20240165092A1 (en)	2021-04-02	2024-05-23	Takeda Pharmaceutical Limited Company	Use of an orexin 2 receptor agonist for post operation recovery
JPWO2023090268A1 (de)	2021-11-17	2023-05-25

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
WO1994019692A1 (en) *	1993-02-18	1994-09-01	The General Hospital Corporation	Alzheimer's disease therapeutics
EP0815134B1 (de) *	1995-03-14	2002-06-05	Praecis Pharmaceuticals Incorporated	VERBINDUNGEN MIT AGGREGATIONS-MODULIERENDEN WIRKUNG AUF DAS AMYLOiD PROTEIN
WO1997021728A1 (en) *	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)

1997
- 1997-08-27 PT PT97940663T patent/PT929574E/pt unknown
- 1997-08-27 JP JP10511914A patent/JP2001500852A/ja not_active Ceased
- 1997-08-27 WO PCT/US1997/015166 patent/WO1998008868A1/en not_active Ceased
- 1997-08-27 DK DK97940663T patent/DK0929574T3/da active
- 1997-08-27 ES ES97940663T patent/ES2245003T3/es not_active Expired - Lifetime
- 1997-08-27 EP EP97940663A patent/EP0929574B1/de not_active Expired - Lifetime
- 1997-08-27 DE DE69733655T patent/DE69733655T2/de not_active Expired - Fee Related
- 1997-08-27 CA CA002262453A patent/CA2262453A1/en not_active Abandoned
- 1997-08-27 AT AT97940663T patent/ATE298765T1/de not_active IP Right Cessation
- 1997-08-27 AU AU42387/97A patent/AU741199B2/en not_active Ceased
- 1997-08-27 EP EP05013789A patent/EP1586584A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
WO1998008868A1 (en)	1998-03-05
HK1021741A1 (en)	2000-06-30
PT929574E (pt)	2005-11-30
AU4238797A (en)	1998-03-19
JP2001500852A (ja)	2001-01-23
DK0929574T3 (da)	2005-10-31
DE69733655D1 (de)	2005-08-04
ES2245003T3 (es)	2005-12-16
EP0929574A1 (de)	1999-07-21
ATE298765T1 (de)	2005-07-15
EP1586584A1 (de)	2005-10-19
DE69733655T2 (de)	2006-04-27
CA2262453A1 (en)	1998-03-05
EP0929574B1 (de)	2005-06-29

Legal Events

Date	Code	Title	Description
2002-03-21	FGA	Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
AU741199B2 (en)	2001-11-22	Modulators of beta-amyloid peptide aggregation comprising D-amino acids
US5985242A (en)	1999-11-16	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6303567B1 (en)	2001-10-16	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en)	2001-08-21	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6610658B1 (en)	2003-08-26	Modulators of μ-amyloid peptide aggregation
WO1998008868A9 (en)	1998-05-28	MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
US5854215A (en)	1998-12-29	Modulators of β-amyloid peptide aggregation
AU769915B2 (en)	2004-02-12	Modulators of beta-amyloid peptide aggregation comprising D-amino acids
AU2004202014B2 (en)	2008-03-06	Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1870419A2 (de)	2007-12-26	Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren
HK1021741B (en)	2006-02-17	Modulators of beta-amyloid peptide aggregation comprising d-amino acids
AU2005203579A1 (en)	2005-09-08	Modulators of beta-amyloid peptide aggregation comprising D-amino acids
HK1117170A (en)	2009-01-09	Modulators of beta-amyloid peptide aggregation comprising d-amino acids
MXPA01008865A (en)	2002-05-09	Modulators of beta-amyloid peptide aggregation comprising d-amino acids
AU2007202669A1 (en)	2007-07-05	Modulators of amyloid aggregation